Peptides

4 articles

Latest news and updates related to peptides

About Peptides coverage

The Peptides news hub on Global Investing News tracks breaking headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Peptides developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Peptides across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.

Explore related topics

AI Streaming Video Tech Crypto EV Economy Cloud Semiconductors Entertainment Mobile Markets Business

Latest Peptides headlines

Market Data

(2)

Classic Cars, Cocktails, Peptides | BTW: Headlines You Should See

Bloomberg•6 months ago

Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides

MarketWatch•7 months ago

Expert Analysis

(1)

‘I wouldn’t dare take these drugs’: how China supplies untested peptides to the west

This investigative report highlights a critical vulnerability in the global pharmaceutical supply chain, specifically focusing on the unregulated flow of synthetic peptides from China to Western markets. Driven by the explosive popularity of GLP-1 agonists like Ozempic and Mounjaro, a gray market has emerged where Chinese chemical labs bypass traditional regulatory oversight to sell 'research grade' compounds directly to consumers and compounding pharmacies. For investors, this underscores a significant 'reputational and safety overhang' for the broader biotech sector, while simultaneously highlighting the massive supply-demand imbalance in the weight-loss drug market. While companies like Novo Nordisk (NVO) and Eli Lilly (LLY) hold patent protections, the proliferation of untested alternatives poses a dual threat: it potentially erodes pricing power and creates legal liabilities for distributors. Furthermore, this exposure could trigger stricter cross-border regulatory crackdowns or ESG-related divestments from companies with opaque Chinese supply chain links. Investors should monitor upcoming FDA and EMA guidance on compounding and imported active pharmaceutical ingredients (APIs), as any safety incident linked to these untested peptides could lead to sudden, sector-wide volatility and increased compliance costs.

Financial Times•9 months ago

Other Sources

(1)

The Booming Business of Chinese Peptides

This Bloomberg report spotlights the rapid expansion of China's peptide industry, driven by increasing demand for these bioactive molecules in pharmaceuticals, cosmetics, and nutritional supplements. The article likely explores the factors contributing to this growth, such as government support, technological advancements, and a large domestic and international market for peptide-based products.

Bloomberg•11 months ago

Get alerts for this topic

Subscribe to receive updates about "Peptides"